Building the DoorDash or UberEats of Psychedelics
October 14th, 2021
App, Exclusive, Psychedelics, Top Story
The psychedelics industry is rapidly growing, with more than 50 publicly traded companies worth billions of dollars. At the same time, the FDA’s approval of Spravato (esketamine) for treatment-resistant depression and the growing body of clinical evidence could provide further tailwinds for the industry over the coming decade and beyond.
Unfortunately, many patients live in areas that don’t have access to psychedelic treatments, like ketamine. And, it’s unrealistic to expect those already suffering from severe mental health conditions to schedule and drive long distances to keep appointments at the few clinics that offer highly effective ketamine therapies in the first place.
Ehave’s (OTC: EHVVF) KetaDASH subsidiary addresses these challenges with a DoorDash or UberEats-style business model. Using a mobile app, patients can instantly connect with highly skilled nurses and get ketamine therapy at their home, office, or hotel. And, the service is already available in over 50 major U.S. cities and Canada.
A Broad Client Base
Ketamine is available for use off-label to treat many medical conditions. Growing research and anecdotal evidence suggest that ketamine could help treat major depressive disorder, bipolar disorder, and post-traumatic stress disorder, translating into a massive patient population underserved by conventional behavioral and pharmaceutical therapies.
In addition to at-home service, KetaDASH provides an intelligent dashboard to measure and report on the efficacy of ketamine treatments. That way, patients and nurses can get a sense of what dosages and patterns are appropriate to manage mental health symptoms without resorting to the guesswork that many ketamine clinics use.
In a recent interview, Ben Kalplan, Ehave President & CEO describes KetaDASH and the company’s wider mission:
In October, the company announced that it hired KGK Science Inc., a contract research organization (CRO), to develop a protocol and informed consent form to support its institutional review board application for a ketamine clinical trial. The company aims to collect certain data points to understand how ketamine influences the brain’s neuroplasticity.
Ehave also plans to expand to accommodate other psychedelic treatments as regulators approve them. In a growing number of clinical trials, psilocybin, MDMA, and other psychedelic substances have shown tremendous promise in treating anxiety, depression, PTSD, and numerous other debilitating mental health conditions.
Building a Leading EHR
Ehave’s overarching goal is to build an evidence-based platform where clinicians and researchers can manage data. Leveraging the blockchain, the company’s cloud-based dashboard seamlessly integrates electronic health records (EHRs) from multiple sources to provide novel insights while lowering administrative costs by up to 90%.
Unlike many tech startups, the company’s dashboard isn’t an untested proof-of-concept—it’s the culmination of years of development alongside one of Canada’s largest hospitals. With HIPAA and GDPR compliance built-in, the platform is ready to expand into the North American hospital market, leveraging KetaDASH as early adopters.
The company intends to build out further with the proposed acquisition of Moksha Digital, a provider of medical imaging software and the creator of the FDA-cleared CuriePACS and CurieRIS solutions for radiological imaging. These solutions aim to bridge the gap between radiologists and referring physicians, addressing a significant unmet need.
Ehave Inc. (OTC: EHVVF) represents a compelling opportunity in the psychedelics space. With its KetaDASH subsidiary, the company is generating early revenue and establishing itself as a leader in providing at-home ketamine IV therapies. Meanwhile, its EHR dashboard provides ample longterm opportunities in the wider medical market.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.